Cargando…

A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid

Pancreatic adenocarcinoma is a common disease considered to be poorly responsive to antiblastic treatment. Recent clinical and preclinical results suggest that a combined treatment of gemcitabine (GEM), 5-flurouracil (5-FU) and folinic acid (FA) offers a clinical benefit in patients with advanced pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Correale, P, Messinese, S, Marsili, S, Ceciarini, F, Pozzessere, D, Petrioli, R, Sabatino, M, Cerretani, D, Pellegrini, M, Di Palma, T, Neri, A, Calvanese, A, Pinto, E, Giorgi, G, Francini, G
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394244/ https://www.ncbi.nlm.nih.gov/pubmed/12865908 http://dx.doi.org/10.1038/sj.bjc.6601045

Ejemplares similares

A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma
por: Correale, P, et al.
Publicado: (2004)

Weekly epirubicin in patients with hormone-resistant prostate cancer
por: Petrioli, R, et al.
Publicado: (2002)

A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2
por: Correale, P, et al.
Publicado: (2001)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Petrioli, R, et al.
Publicado: (2004)

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
por: De Vita, F, et al.
Publicado: (2005)

Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I–II study
por: Avallone, A, et al.
Publicado: (2006)

Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin
por: Gonzalez, M A, et al.
Publicado: (2003)

5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?
por: Kerr, D. J.
Publicado: (1989)

Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801
por: Takayama, Koichi, et al.
Publicado: (2020)

Fluorouracil/folinic acid/oxaliplatin: Various toxicities: 2 case reports
Publicado: (2021)

Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation.
por: Jebb, S. A., et al.
Publicado: (1994)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
por: Modest, Dominik Paul, et al.
Publicado: (2022)

Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck
por: Sukari, Ammar, et al.
Publicado: (2015)

Erratum to: Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer
por: Kuehr, Thomas, et al.
Publicado: (2004)

Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity
por: Fischel, J L, et al.
Publicado: (2002)

Weekly chemotherapy in advanced prostatic cancer.
por: Francini, G., et al.
Publicado: (1993)

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer
por: Conroy, T, et al.
Publicado: (2008)

A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer
por: Tomao, Silverio, et al.
Publicado: (2006)

Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Therapy in Patients with Advanced Pancreatic Cancer: A Multicenter, Prospective Observational Study
por: Miki, Masami, et al.
Publicado: (2022)

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
por: Fischel, J-L, et al.
Publicado: (2001)

Combined effects of 5-Fluorouracil, Folinic acid and Oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy
por: Prete, Salvatore P, et al.
Publicado: (2008)

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.
por: Mackean, M. J., et al.
Publicado: (1998)

Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma.
por: Zaniboni, A., et al.
Publicado: (1988)

Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study
por: Addeo, Raffaele, et al.
Publicado: (2019)

Mifepristone in Fibroids: Comparative Study of Safety and Efficacy of Biweekly Dosage Vs Daily Dosage Schedule
por: Shaikh, Neelofar, et al.
Publicado: (2021)

Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo
por: Di Paolo, Antonello, et al.
Publicado: (2017)

Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma
por: Machover, David, et al.
Publicado: (2022)

A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastases.
por: Anderson, J. H., et al.
Publicado: (1992)

A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases.
por: Warren, H. W., et al.
Publicado: (1994)

High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma.
por: Highley, M. S., et al.
Publicado: (1993)

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
por: Heinrich, K., et al.
Publicado: (2023)

Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas.
por: Johnson, P. W., et al.
Publicado: (1991)

Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment
por: Negrei, Carolina, et al.
Publicado: (2016)

Posterior reversible encephalopathy syndrome while receiving irinotecan with fluorouracil and folinic acid for metastatic gastric cancer
por: Abughanimeh, Omar K, et al.
Publicado: (2017)

Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer
por: Rehman, Hasan, et al.
Publicado: (2020)

Reply: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Francini, G, et al.
Publicado: (2004)

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
por: Souglakos, J, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_eia9q6fhdpkq2s7u9lh4uofeiv